The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, has purchased 6,000 equity shares through open market transactions on March 12 and March 13, 2026 (2,400 and 3,600 shares respectively). The acquisition raised his holding from 7,05,700 shares (30.92%) to 7,11,700 shares (31.18%) of the company, an increase of 0.26 percentage points in promoter stake. The shares were acquired in his personal capacity and the disclosure was filed under SEBI SAST Regulation 29(2). The total equity share capital of the company remains unchanged at 22,82,400 shares.
This is a small open-market purchase by the promoter, signalling modest confidence in the company. However, the 0.26% increase is minor and unlikely to materially move the stock price. Shareholders should note the promoter's stake is now just above 31%, leaving room for further creeping acquisitions before the next 5% open-offer trigger at 35%.